SCHEMBL4212864

SCHEMBL4212864

Cc1ccccc1Nc1cc(N2CCc3ccccc32)ccc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 5/20 0.50
KDM6B O15054 2/20 0.48
AKR1C3 P42330 3/20 0.42
AKR1C2 P52895 3/20 0.42
AKR1B10 O60218 2/20 0.42
AKR1B1 P15121 2/20 0.42
AKR1C1 Q04828 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 2/20 0.42
TRPA1 O75762 1/20 0.42
ABCB11 O95342 1/20 0.42
DHFR P00374 1/20 0.42
MPO P05164 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CHRM1 P11229 1/20 0.42
CYP2C9 P11712 1/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4220968 0.86 KDM4C (0.51) KDM4CKDM6BAKR1C3AKR1C2MEN1
SCHEMBL14428223 0.82 KDM4C (0.49) KDM4CKDM6BMEN1KMT2ASMN1; SMN2
SCHEMBL4225357 0.81 KDM4C (0.47) KDM4CKDM6BAKR1C3AKR1C2MEN1
SCHEMBL4215444 0.81 KDM4C (0.49) KDM4CKDM6BAKR1C3AKR1C2LMNA
SCHEMBL2269025 0.80 MAPT (0.50) KDM4CKDM6BMEN1KMT2ALMNA
SCHEMBL13890895 0.77 NPC1 (0.48) KDM4CKDM6BMEN1KMT2ATDP1
SCHEMBL4213805 0.76 KDM4C (0.43) KDM4CKDM6BMEN1KMT2AMPO
SCHEMBL13890893 0.72 ALDH1A1 (0.52) KDM4CMEN1KMT2ALMNATDP1
SCHEMBL4186922 0.72 AKR1C3 (0.60) AKR1C3AKR1C2AKR1B10AKR1B1AKR1C1
SCHEMBL3237547 0.71 AKR1C3 (0.66) AKR1C3AKR1C2AKR1B10AKR1B1AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 KDM4C 1892/4885KDM6B 2594/4885AKR1C3 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.